Thalidomide, an antiangiogenic agent with clinical activity in cancer.
Despite the teratogenic past of thalidomide, there is recent evidence indicating the drug's efficacy in the management of various diseases from immune disorders to cancers. The history, pharmacodynamic and pharmacokinetic properties of thalidomide in the clinic are discussed in this review article.
Molecular Pharmacology Section, Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
S S W
SS
Ng
M
M
Brown
W D
WD
Figg
D020533:Angiogenesis Inhibitors / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000818:Animals; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000378:metabolism; D013792:Thalidomide / Q000737:chemistry* / Q000493:pharmacokinetics / Q000627:therapeutic use*
D020533:Angiogenesis Inhibitors; D013792:Thalidomide